Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Two-part, Multicenter, Non-randomized, Open-label, Multiple Dose, First-in-human Study of DS-1062a in Subjects With Advanced Solid Tumors

Trial Profile

Phase 1, Two-part, Multicenter, Non-randomized, Open-label, Multiple Dose, First-in-human Study of DS-1062a in Subjects With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DS-1062 (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 10 Sep 2019 Results (data cutoff April 12, 2019) (n=39) assessing safety and tolerability of DS-1062 (DS-1062a) in patients with unresectable advanced and relapsed non-small-cell lung cancer (NSCLC) presented at the 20th World Conference on Lung Cancer.
    • 10 Sep 2019 Results published in the Daiichi Sankyo Company Media Release.
    • 10 Sep 2019 According to an Daiichi Sankyo Company media release, data from this study were featured today in a Mini Oral Session at the IASLC 2019 World Conference on Lung Cancer (#WCLC19).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top